PriceTargets.com logo

Can-Fite BioPharma - CANF Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $34.00
  • Forecasted Upside: 1,163.94%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.69 As of 06/8/2023 01:00 AM ET
▲ +0.08 (3.07%)

This chart shows the closing price for CANF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Can-Fite BioPharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CANF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CANF

Analyst Price Target is $34.00
▲ +1,163.94% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Can-Fite BioPharma in the last 3 months. The average price target is $34.00, with a high forecast of $34.00 and a low forecast of $34.00. The average price target represents a 1,163.94% upside from the last price of $2.69.

This chart shows the closing price for CANF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Can-Fite BioPharma. This rating has held steady since March 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/15/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/15/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/13/2023HC WainwrightReiterated RatingBuy$34.00
1/3/2023Dawson JamesDowngradeBuy ➝ Neutral
1/7/2022HC WainwrightReiterated RatingBuy$50.00
11/30/2021Alliance Global PartnersLower TargetBuy$90.00 ➝ $82.50
6/24/2021AegisInitiated CoverageBuy$50.00
6/15/2021Alliance Global PartnersInitiated CoverageBuy
2/26/2021HC WainwrightReiterated RatingBuy
7/2/2020HC WainwrightReiterated RatingBuy$50.00
5/18/2020HC WainwrightReiterated RatingBuy$50.00
2/24/2020HC WainwrightReiterated RatingBuy$50.00
10/31/2019HC WainwrightReiterated RatingBuy ➝ Positive$30.00 ➝ $50.00
9/24/2019HC WainwrightLower TargetBuy$30.00
3/27/2019HC WainwrightReiterated RatingBuy
3/26/2019HC WainwrightReiterated RatingBuy
10/31/2018HC WainwrightSet TargetBuy$80.00
9/6/2018HC WainwrightSet TargetBuy$80.00
8/31/2018HC WainwrightSet TargetBuy$80.00
8/22/2018HC WainwrightSet TargetBuy$80.00
8/6/2018HC WainwrightSet TargetBuy$80.00
6/15/2018Maxim GroupReiterated RatingHold
6/13/2018HC WainwrightReiterated RatingBuy$80.00
(Data available from 6/8/2018 forward)

News Sentiment Rating

-0.17 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
11/10/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
12/10/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
1/9/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
2/8/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
3/10/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
4/9/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
5/9/2023
  • 1 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
6/8/2023

Current Sentiment

  • 1 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Can-Fite BioPharma logo
Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. Its product pipeline include Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.
Read More

Today's Range

Now: $2.69
Low: $2.67
High: $2.72

50 Day Range

MA: $2.34
Low: $1.64
High: $2.91

52 Week Range

Now: $2.69
Low: $1.52
High: $11.20

Volume

5,663 shs

Average Volume

72,822 shs

Market Capitalization

$9.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.29

Frequently Asked Questions

What sell-side analysts currently cover shares of Can-Fite BioPharma?

The following Wall Street analysts have issued stock ratings on Can-Fite BioPharma in the last twelve months: Dawson James, HC Wainwright, and StockNews.com.
View the latest analyst ratings for CANF.

What is the current price target for Can-Fite BioPharma?

1 Wall Street analysts have set twelve-month price targets for Can-Fite BioPharma in the last year. Their average twelve-month price target is $34.00, suggesting a possible upside of 1,163.9%. HC Wainwright has the highest price target set, predicting CANF will reach $34.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $34.00 for Can-Fite BioPharma in the next year.
View the latest price targets for CANF.

What is the current consensus analyst rating for Can-Fite BioPharma?

Can-Fite BioPharma currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CANF will outperform the market and that investors should add to their positions of Can-Fite BioPharma.
View the latest ratings for CANF.

What other companies compete with Can-Fite BioPharma?

Other companies that are similar to Can-Fite BioPharma include Jaguar Health, Lixte Biotechnology, Catalyst Biosciences, Aridis Pharmaceuticals and Avenue Therapeutics. Learn More about companies similar to Can-Fite BioPharma.

How do I contact Can-Fite BioPharma's investor relations team?

Can-Fite BioPharma's physical mailing address is 10 Bareket Street, Kiryat Matalon P.O. Box 7537, PETAH TIKVA, 49170, Israel. The biotechnology company's listed phone number is (723) 924-1114 and its investor relations email address is inf[email protected]. The official website for Can-Fite BioPharma is www.canfite.co.il. Learn More about contacing Can-Fite BioPharma investor relations.